Market Place
Sourcing Support
Travere Therapeutics to Present at Upcoming Investor Conferences
25 Nov 2024 //
GLOBENEWSWIRE
Travere Therapeutics Reports Inducement Grants Under Nasdaq
13 Nov 2024 //
GLOBENEWSWIRE
Travere Completes Public Offering, Underwriters’ Option Exercise
12 Nov 2024 //
GLOBENEWSWIRE
Travere Therapeutics Announces Public Offering of Stock
07 Nov 2024 //
GLOBENEWSWIRE
Travere Therapeutic Announces Pricing of Public Offering of Stock
07 Nov 2024 //
GLOBENEWSWIRE
Travere Therapeutics to Present at Upcoming Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Travere Therapeutics Reports Third Quarter 2024 Financial Results
31 Oct 2024 //
GLOBENEWSWIRE
Travere Therapeutics Reinforces FILSPARI® Benefit in IgAN
26 Oct 2024 //
GLOBENEWSWIRE
Travere Therapeutics to Report Third Quarter 2024 Financial Results
21 Oct 2024 //
GLOBENEWSWIRE
Travere And CSL Announce Approval Of FILSPARI® For IgA Nephropathy
17 Oct 2024 //
GLOBENEWSWIRE
Travere Therapeutics to Present Abstracts at ASN Kidney Week 2024
14 Oct 2024 //
GLOBENEWSWIRE
Travere pauses trial enrollment over manufacturing scale-up woes
27 Sep 2024 //
FIERCE PHARMA
Travere`s Benralizumab Receives Approval in the U.S.
17 Sep 2024 //
FDA
Travere Therapeutics Reports Inducement Grants
12 Sep 2024 //
GLOBENEWSWIRE
Travere To Present At Cantor Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
Ligand Partner Travere Gets Full FDA Approval For FILSPARI In IgA
06 Sep 2024 //
BUSINESSWIRE
Despite trial scare, Travere`s IgAN drug wins full FDA approval
06 Sep 2024 //
FIERCE PHARMA
Travere`s Filspari Gets Full FDA Approval For Kidney Disease
05 Sep 2024 //
FIERCE PHARMA
Travere To Present At Inborn Errors Of Metabolism Symposium 2024
22 Aug 2024 //
GLOBENEWSWIRE
Travere Therapeutics to Present at Upcoming Investor Conferences
06 Aug 2024 //
GLOBENEWSWIRE
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01 Aug 2024 //
GLOBENEWSWIRE
Travere Therapeutics to Report Second Quarter 2024 Financial Results
25 Jul 2024 //
GLOBENEWSWIRE
Pharma is Missing the Mark: Social Media`s Power Proven by Physician Influencers
15 Jul 2024 //
PR NEWSWIRE
Travere to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
08 Jul 2024 //
GLOBENEWSWIRE
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
11 Jun 2024 //
GLOBENEWSWIRE
Travere Reports Inducement Grants Under Nasdaq Listing Rule
15 May 2024 //
GLOBENEWSWIRE
Travere To Present At Kidney Meetings In Spring 2024
09 May 2024 //
GLOBENEWSWIRE
Travere Therapeutics to Present at Upcoming Investor Conferences
08 May 2024 //
GLOBENEWSWIRE
Travere Therapeutics Reports First Quarter 2024 Financial Results
06 May 2024 //
GLOBENEWSWIRE
Travere Therapeutics to Report First Quarter 2024 Financial Results
29 Apr 2024 //
GLOBENEWSWIRE
FILSPARI Approved in EU for IgA Nephropathy
24 Apr 2024 //
PR NEWSWIRE
Travere to Present Abstracts at the Society for IMD and GMDI
04 Apr 2024 //
GLOBENEWSWIRE
Travere to Present Abstracts on FILSPARI in IgA Nephropathy at World Congress
03 Apr 2024 //
GLOBENEWSWIRE
Travere Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Mar 2024 //
GLOBENEWSWIRE
Travere Submits sNDA to the FDA Seeking Full Approval of FILSPARI
11 Mar 2024 //
GLOBENEWSWIRE
Travere Therapeutics to Present at Upcoming Investor Conferences
26 Feb 2024 //
GLOBENEWSWIRE
Travere drug for rare kidney condition recommended for EU approval
24 Feb 2024 //
REUTERS
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Travere to Report Fourth Quarter and Full Year 2024 Financial Results
08 Feb 2024 //
GLOBENEWSWIRE
Travere to Present at the Guggenheim 6th Annual Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma
25 Jan 2024 //
GLOBENEWSWIRE
Travere Therapeutics Provides Corporate Update and 2024 Outlook
08 Jan 2024 //
GLOBENEWSWIRE
Travere to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase
14 Dec 2023 //
GLOBENEWSWIRE
Travere cuts 20% of workforce, aims to win full nod for Filspari
05 Dec 2023 //
FIERCE PHARMA
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN
04 Dec 2023 //
GLOBENEWSWIRE
Travere Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
21 Nov 2023 //
GLOBENEWSWIRE
Travere Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Travere looks to consistent benefit to stay in kidney disease
03 Nov 2023 //
FIERCE PHARMA
Travere Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN
03 Nov 2023 //
GLOBENEWSWIRE
Travere Therapeutics to Report Third Quarter 2023 Financial Results
24 Oct 2023 //
GLOBENEWSWIRE
Travere Therapeutics to Present Abstracts at the ASN Kidney Week 2023
13 Oct 2023 //
GLOBENEWSWIRE
Travere Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Oct 2023 //
GLOBENEWSWIRE
Travere Therapeutics to Present Abstracts at the 17th International Symposium
26 Sep 2023 //
GLOBENEWSWIRE
Travere`s Filspari misses the mark in rare kidney disease trial
22 Sep 2023 //
FIERCE PHARMA
Travere Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI
21 Sep 2023 //
GLOBENEWSWIRE
Travere Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Sep 2023 //
GLOBENEWSWIRE
Travere Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
05 Sep 2023 //
GLOBENEWSWIRE
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
31 Aug 2023 //
GLOBENEWSWIRE
